convent
vaccin
extrem
success
prevent
infect
pathogen
express
rel
conserv
antigen
antibodymedi
effector
mechan
thank
vaccin
diseas
erad
mortal
due
infecti
diseas
significantli
reduc
howev
still
mani
infect
prevent
vaccin
repres
major
caus
mortal
worldwid
infect
caus
pathogen
high
degre
antigen
variabl
control
antibodi
requir
mix
humor
cellular
immun
respons
novel
technolog
antigen
discoveri
express
formul
allow
develop
vaccin
better
cope
pathogen
divers
trigger
multifunct
immun
respons
addit
applic
new
genom
assay
system
biolog
approach
human
immunolog
help
better
identifi
vaccin
correl
protect
avail
novel
vaccin
technolog
togeth
knowledg
distinct
human
immun
respons
requir
prevent
differ
type
infect
help
ration
design
effect
vaccin
convent
approach
fail
vaccin
one
effect
measur
control
infecti
diseas
centuri
believ
vaccin
save
million
live
per
year
global
smallpox
erad
worldwid
polio
almost
elimin
viral
mump
rubella
measl
varicella
rotaviru
bacteri
tetanu
diphteria
haemophilu
influenza
streptococcu
pneumonia
meningococcu
group
c
diseas
tradit
affect
childhood
world
prevent
vaccin
giv
giv
besid
paediatr
adult
popul
vaccin
success
extend
adolesc
elderli
immunocompromis
subject
pregnant
women
although
therapeut
vaccin
target
ongo
chronic
infecti
diseas
yet
develop
effect
vaccin
exist
prevent
chronic
infect
human
papilloma
viru
hpv
hepat
b
viru
hbv
case
caus
cancer
summari
vaccin
continu
repres
success
stori
plotkin
et
al
levin
et
al
howev
still
long
list
virus
eg
hepat
c
viru
hcv
human
immunodefici
viru
hiv
dengu
respiratori
syncyti
viru
rsv
cytomegaloviru
cmv
parasit
eg
plasmodium
leishmania
schistosoma
trypanosoma
bacteria
eg
mycobacterium
tuberculosi
tb
group
streptococcu
ga
group
b
streptococcu
gb
staphylococcu
aureu
meningococcu
group
b
menb
shigella
pathogen
escherichia
coli
prevent
vaccin
infecti
diseas
still
major
caus
death
disabl
worldwid
thirtythre
million
peopl
current
infect
hiv
caus
million
death
per
year
global
summari
aid
epidem
http
wwwunaidsorgglobalreport
malaria
tuberculosi
togeth
kill
almost
million
peopl
everi
year
report
http
wwwwhoint
total
number
death
increas
even
includ
caus
vaccin
prevent
infect
area
world
vaccin
avail
popul
estim
million
children
year
age
die
everi
year
result
vaccin
prevent
infect
giv
giv
futur
increas
avail
exist
vaccin
develop
new
vaccin
tremend
impact
reduc
mortal
disabl
caus
infecti
diseas
worldwid
tradit
vaccin
base
inactiv
attenu
pathogen
purifi
pathogen
subunit
toxin
protein
polysaccharid
effici
prevent
infect
pathogen
low
degre
antigen
variabl
vaccin
work
mainli
elicit
function
antibodi
neutral
viral
invas
ii
neutral
bacteri
toxin
iii
induc
opsonophagocytosi
complementmedi
kill
bacteria
germain
also
possibl
develop
effect
vaccin
prevent
pathogen
moder
degre
antigen
variabl
exist
multipl
strain
problem
solv
develop
multival
vaccin
combin
multipl
antigen
direct
one
strain
serotyp
formul
four
differ
viruslik
particl
elicit
neutral
antibodi
assembl
one
hpv
vaccin
pomfret
et
al
case
bacteri
pathogen
polysaccharid
deriv
capsul
variou
strain
conjug
protein
carrier
mix
vaccin
multival
glycoconjug
vaccin
develop
pneumococcu
recent
vaccin
prymula
schuerman
duggan
menigococcu
two
vaccin
licens
c
w
serotyp
pace
glycoconjug
strategi
could
adopt
meningococcu
serotyp
b
capsular
polysaccharid
similar
self
antigen
case
tradit
techniqu
unabl
identifi
univers
vaccin
menb
strain
novel
approach
base
genom
inform
call
revers
vaccinolog
appli
describ
detail
next
paragraph
giuliani
et
al
tradit
vaccin
also
abl
prevent
diseas
caus
pathogen
influenza
flu
present
differ
strain
clade
chang
antigen
target
neutral
antibodi
haemagglutinin
ha
everi
season
case
problem
solv
produc
trival
vaccin
chang
composit
vaccin
everi
year
howev
flu
vaccin
increas
breadth
would
greatli
help
manufactur
process
increas
vaccin
efficaci
investig
suggest
variou
strategi
develop
univers
flu
vaccin
capabl
prevent
infect
exist
flu
strain
nabel
fauci
dormitz
et
al
univers
flu
vaccin
would
ideal
prevent
least
mitig
risk
pandem
outbreak
origin
unpredict
flu
strain
anim
origin
today
vaccin
fail
prevent
infect
pathogen
character
high
mutat
rate
abl
modifi
target
antigen
evad
antibodi
respons
cours
infect
addit
vaccin
ineffici
prevent
infect
control
antibodi
cellular
immun
challeng
futur
even
higher
consid
infect
caus
variabl
pathogen
hiv
hcv
probabl
prevent
antibodi
requir
combin
humor
cellular
respons
mcelrath
hayn
success
futur
vaccin
highli
variabl
pathogen
depend
abil
induc
univers
b
cell
respons
character
product
function
antibodi
crossreact
multipl
variant
antigen
howev
case
univers
antibodi
respons
may
enough
protect
must
complement
abil
elicit
effici
respons
sallusto
et
al
case
similarli
antibodi
assay
neutral
opsonophagocytosi
bactericid
kill
use
correl
protect
vaccin
work
b
cell
new
cellular
assay
evalu
vaccin
efficaci
must
develop
highlight
sever
expert
field
want
understand
cellular
correl
vaccin
protect
suffici
count
frequenc
antigenspecif
cell
respons
vaccin
import
assess
qualiti
cytokin
make
differenti
state
central
memori
effector
memori
effector
cell
receptor
express
surfac
may
predict
local
case
infect
germain
sallusto
et
al
follow
paragraph
focu
strategi
recent
employ
cope
bacteri
viral
divers
technolog
appli
vaccin
futur
prevent
highli
variabl
pathogen
describ
new
technolog
includ
adjuv
deliveri
system
viral
vector
use
shape
cellular
humor
immun
respons
vaccin
final
review
new
system
biolog
approach
better
understand
human
correl
vaccin
efficaci
vaccin
discoveri
process
call
revers
vaccinolog
effici
adopt
bacteri
pathogen
high
degre
antigen
variabl
circul
multipl
strain
sett
rappuoli
summari
genom
inform
multipl
strain
use
select
surfaceexpos
antigen
conserv
silico
select
antigen
express
recombin
protein
use
immun
mice
antigen
gave
best
bactericid
antibodi
respons
absenc
correl
protect
best
surviv
rate
anim
challeng
studi
select
prototyp
vaccin
approach
adopt
develop
vaccin
abl
prevent
infect
men
b
strain
mice
giuliani
et
al
preclin
result
confirm
clinic
trial
adult
infant
licenc
applic
recent
submit
europ
findlow
et
al
snape
et
al
approach
adopt
develop
vaccin
abl
protect
circul
strain
gb
case
antigen
identifi
revers
vaccinolog
unknown
character
often
help
understand
biolog
pathogen
exampl
protect
antigen
identifi
revers
vaccinolog
ga
found
compon
previous
unknown
piluslik
structur
mediat
bacteri
adhes
host
cell
lauer
et
al
futur
revers
vaccinolog
appli
gener
univers
proteinbas
vaccin
variabl
pathogen
ga
pneumonia
pathogen
e
coli
strain
revers
vaccinolog
applic
develop
vaccin
virus
high
mutat
rate
contrast
shown
interrog
human
b
cell
respons
infect
lead
identif
crossreact
protect
epitop
may
repres
structur
determin
broadli
protect
vaccin
process
call
analyt
vaccinolog
base
recent
develop
sever
method
gener
human
monoclon
antibodi
human
blood
sampl
review
sallusto
et
al
one
approach
use
analys
human
b
cell
compart
select
total
memori
b
cell
infect
vaccin
subject
immort
new
effici
method
screen
antibodi
function
assay
traggiai
et
al
altern
possibl
select
plasma
cell
induc
vaccin
wrammert
et
al
antigenspecif
memori
b
cell
scheid
et
al
rescu
antibodi
singl
cell
pcr
antibodi
express
heterolog
cell
use
function
assay
liao
et
al
approach
possibl
analys
human
antibodi
repertoir
gener
infect
variabl
pathogen
flu
hiv
case
broadli
neutral
human
monoclon
antibodi
identifi
epitop
recogn
map
flucrossneutr
antibodi
recogn
conserv
region
stem
ha
protein
ekiert
et
al
corti
et
al
antibodi
prevent
ha
bind
receptor
interfer
conform
chang
ha
requir
membran
fusion
sui
et
al
case
hiv
extrem
effici
monoclon
antibodi
crossneutr
primari
isol
test
form
pseudovirus
bind
conserv
epitop
bind
site
env
protein
wu
et
al
approach
use
identif
human
monoclon
antibodi
neutral
human
cmv
infect
case
analyt
vaccinolog
shown
protect
neutral
epitop
gener
pentamer
protein
complex
repres
new
candid
vaccin
develop
macagno
et
al
identif
conserv
epitop
hiv
flu
target
broadli
neutral
antibodi
first
step
develop
univers
vaccin
lot
work
need
done
ration
design
express
target
antigen
eg
ha
env
form
stabil
crossreact
epitop
make
suffici
immunogen
way
achiev
goal
deep
structur
knowledg
candid
antigen
fig
structur
inform
also
exploit
gener
chimer
protein
contain
protect
epitop
deriv
multipl
variant
antigen
approach
recent
use
novel
menb
candid
vaccin
ration
design
assembl
epitop
three
differ
variant
menb
factor
hbind
protein
scarselli
et
al
identif
protect
epitop
product
ration
design
antigen
induc
crossneutr
antibodi
enough
produc
effect
vaccin
antigen
need
formul
antigen
deliveri
system
immunomodul
must
insert
viral
nucleic
acid
express
vector
well
known
long
time
adjuv
increas
amount
qualiti
durat
antibodi
respons
vaccin
empir
deriv
adjuv
aluminium
salt
use
human
vaccin
year
howev
last
decad
knowledg
human
innat
immun
system
rapidli
progress
lead
identif
novel
class
molecul
tolllik
receptor
tlr
riglik
receptor
rlr
nodlik
receptor
nlr
ctype
lectin
valid
target
develop
new
immunomodul
review
issu
carlo
gutzman
et
al
press
parallel
signific
amount
work
done
advanc
antigen
deliveri
system
includ
liposom
viru
like
particl
nanoparticl
use
formul
antigen
futur
vaccinolog
immunomodul
vaccin
allow
codeliveri
bachmann
jen
despit
univers
acknowledg
potenti
vaccin
adjuv
two
compound
licens
human
use
usa
alum
agonist
mpl
other
europ
virosom
oil
water
emuls
coffman
et
al
mbow
et
al
licens
adjuv
demonstr
tremend
impact
vaccin
mpl
adsorpt
alumhpv
vaccin
promot
higher
neutral
antibodi
titr
increas
memori
b
cell
frequenc
giannini
et
al
addit
oil
water
emuls
pandem
flu
vaccin
requir
protect
seroconvers
promot
crossreact
versu
variou
heterolog
clade
banzhoff
et
al
schwarz
et
al
besid
antibodi
enhanc
memori
b
cell
respons
vaccin
galli
et
al
b
interestingli
increas
breadth
respons
induc
associ
recognit
increas
number
epitop
ha
khurana
et
al
data
suggest
adjuv
chang
amount
also
qualiti
humor
respons
vaccin
allow
better
coverag
less
immunodomin
epitop
may
import
crossprotect
mani
new
adjuv
isol
combin
clinic
trial
promis
result
one
exampl
combin
liposom
mpl
use
malaria
phase
ii
clinic
trial
achiev
first
time
protect
cohen
et
al
anoth
promis
adjuv
clinic
develop
agonist
cpg
oligonucleotid
steinhagen
et
al
addit
mani
tlr
agonist
polyi
c
flagellin
lipoprotein
alreadi
test
human
combin
variou
antigen
deliveri
system
steinhagen
et
al
easi
predict
futur
immunomodul
antigen
deliveri
system
avail
use
human
vaccin
use
compound
variou
combin
greatli
help
ration
design
vaccin
distinct
properti
aim
gener
protect
adapt
immun
respons
adjuv
effici
boost
antibodi
respons
subunit
vaccin
howev
induct
subunit
vaccin
reli
crosspresent
mechan
gener
poor
adjuv
saponinbas
iscom
shown
abil
increas
crosspresent
anim
human
studi
drane
et
al
sun
et
al
howev
human
iscom
produc
partial
respons
drane
et
al
probabl
best
approach
induc
mhcimedi
immun
respons
use
nucleic
acid
viral
vector
mediat
express
select
vaccin
antigen
directli
cytoplasm
target
cell
liu
review
issu
oliv
elbert
press
sever
dna
replic
nonrepl
viral
vector
test
clinic
trial
howev
none
licens
human
use
one
wellknown
exampl
nonrepl
vector
adenovirusderiv
vector
use
fig
human
immunolog
help
develop
novel
crossprotect
vaccin
human
sampl
vaccin
convalesc
subject
use
isol
crossreact
monoclon
antibodi
vitro
function
assay
viral
neutral
bacteri
kill
isol
antibodi
use
identifi
protect
antigen
epitop
structur
vaccinolog
method
appli
express
stabil
antigen
protect
conform
final
candid
antigen
formul
appropri
adjuv
increas
immunogen
step
hiv
trial
induc
strong
respons
subject
preexist
antibodi
mcelrath
et
al
unfortun
trial
show
good
respons
correl
prevent
hiv
infect
suggest
probabl
balanc
immun
respons
includ
cell
crossneutr
antibodi
requir
buchbind
et
al
mcelrath
et
al
mcelrath
hayn
one
way
obtain
multifunct
respons
use
prime
boost
regimen
prime
express
vector
target
respons
follow
boost
subunit
vaccin
improv
antibodi
product
recent
primeboost
strategi
implement
hiv
trial
conduct
thailand
subject
prime
canarypox
vector
encod
gag
env
proteas
boost
subunit
vaccin
trial
show
first
time
efficaci
acquisit
rerksngarm
et
al
result
encourag
consid
proof
concept
hiv
vaccin
strategi
appli
howev
work
need
done
optim
vaccin
use
effici
express
vector
ration
design
env
antigen
elicit
crossneutr
antibodi
formul
adequ
immunomodul
deliveri
system
although
trial
shown
benefit
primeboost
strategi
prevent
vaccin
hiv
still
clear
effector
mechan
elicit
vaccin
protect
subject
hiv
infect
difficult
intracellular
pathogen
hiv
hcv
protect
probabl
aris
integr
differ
effector
mechan
appropri
qualiti
therefor
correl
protect
easili
measur
simpl
antibodi
cell
assay
requir
complex
readout
progress
genom
possibl
gener
lot
highthroughput
data
human
blood
sampl
includ
rna
express
profil
measur
dna
microarray
protein
express
profil
measur
mass
spectrometri
analysi
genom
polymorph
measur
deep
sequenc
system
biolog
requir
integr
genom
data
data
obtain
subject
classic
immunolog
assay
antibodi
neutral
bactericid
activ
elisa
cell
character
elispot
facsintracellular
stain
prolifer
cytotox
activ
pulendran
et
al
review
issu
david
klatzmann
press
addit
innov
immunolog
assay
avail
antibodi
repertoir
analysi
singl
cell
phosphospecif
flow
cytometri
krutzik
et
al
allow
evalu
detail
qualiti
humor
cellular
respons
vaccin
system
biolog
approach
alreadi
success
appli
human
vaccin
yellow
fever
vaccin
gaucher
et
al
querec
et
al
studi
shown
possibl
predict
efficaci
vaccin
measur
transcriptom
pbmc
hour
vaccin
interestingli
predict
innat
immun
signatur
obviou
involv
gene
associ
gener
adapt
respons
new
biolog
inform
discov
system
biolog
approach
help
better
understand
mechan
action
vaccin
exploit
ration
design
improv
vaccin
adjuv
target
protect
gene
pathway
pulendran
et
al
prevent
vaccin
major
success
medicin
last
centuri
howev
still
mani
infecti
diseas
caus
million
death
everi
year
worldwid
convent
approach
fail
develop
effect
vaccin
pathogen
howev
great
hope
futur
base
new
technolog
avail
vaccin
develop
also
increas
abil
interrog
human
immun
respons
integr
complex
readout
comput
method
think
vaccinolog
futur
less
empir
use
learn
human
immunolog
antigen
design
direct
deep
knowledg
crossprotect
epitop
human
adjuv
express
vector
select
base
type
humor
cellular
immun
respons
correl
protect
ration
vaccin
design
hope
allow
develop
effect
prevent
vaccin
remain
difficult
target
includ
hiv
malaria
tuberculosi
